Virtu Financial’s ProQR Therapeutics PRQR Stock Holding History

Virtu Financial’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22K	Buy	+11,626	New	+$19.1K	﹤0.01%	1336
2025 Q1	–	Sell	-31,158	Closed	-$83K	–	1907
2024 Q4	$83K	Buy	+31,158	New	+$98.9K	﹤0.01%	1061
2024 Q2	–	Sell	-25,943	Closed	-$59K	–	1772
2024 Q1	$59K	Sell	25,943 -8,961	-26%	-$19.2K	﹤0.01%	997
2023 Q4	$69K	Buy	+34,904	New	+$53.6K	0.01%	1117
2023 Q2	–	Sell	-94,564	Closed	-$201K	–	1933
2023 Q1	$201K	Buy	+94,564	New	+$289K	0.02%	751
2022 Q3	–	Sell	-61,425	Closed	-$48K	–	2126
2022 Q2	$48K	Buy	+61,425	New	+$45.8K	﹤0.01%	1130
2021 Q3	–	Sell	-13,883	Closed	-$94K	–	1860
2021 Q2	$94K	Buy	+13,883	New	+$89.5K	0.01%	1222
2017 Q4	–	Sell	-13,150	Closed	-$64K	–	2863
2017 Q3	$64K	Buy	+13,150	New	+$68.3K	﹤0.01%	2182

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Virtu Financial's PRQR Position: Q2 2026 in Review

Virtu Financial opened a new position in ProQR Therapeutics (PRQR) in Q2 2026: 11,626 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #1336 among its holdings. This is a return to the name: Virtu Financial previously reported a position in PRQR as recently as Q4 2024.

Virtu Financial first reported a position in PRQR in Q3 2017 and has held it in 8 quarters since. The position peaked at $201K in Q1 2023. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

Virtu Financial held 11,626 shares of ProQR Therapeutics worth $22K as of Q2 2026.
ProQR Therapeutics was a new Virtu Financial position in Q2 2026.
ProQR Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1336 holding.
Virtu Financial first reported a position in ProQR Therapeutics in Q3 2017 and has held it in 8 quarters since.
Virtu Financial's ProQR Therapeutics position peaked at $201K in Q1 2023.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.